Interpret the relevant information about Pegcetacoplan-Empaveli’s inclusion in medical insurance

Pegcetacoplan (Pegcetacoplan), trade nameEmpaveli, has not yet been launched in the Chinese market, nor has it been included in China's medical insurance directory. Although the drug has been approved in countries such as the United States and Europe and has shown significant efficacy in the treatment of immune-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy, its launch in the Chinese market still needs to go through the approval process of the National Medical Products Administration (NMPA).

Since Pegtak is a relatively new drug that involves the inhibition of the complement system, its promotion in the Chinese market faces certain challenges. First, the manufacturer of Pegtak needs to provide sufficient clinical data to prove its efficacy and safety in Chinese patients, especially when compared with local treatments. Secondly, Pegtak’s high price may also become an obstacle to its entry into China’s medical insurance. At present, the pricing of Pegtak in overseas markets is relatively high, especially for patients with PNH and C3-related kidney disease who require long-term treatment, which also brings difficulties to Chinese patients in purchasing.

However, as the Chinese government continues to pay more attention to rare diseases and innovative drugs, especially its research on complement inhibitor drugs, it is possible that Pegtak will be approved and included in medical insurance in China in the future. Patients who need such drugs can also obtain treatment through international drug procurement channels if their financial conditions permit.

In general, as a new type of complement inhibitor, although Pegtak is not currently on the market in China, with the verification of its efficacy globally and changes in China's medical policies, it is expected to obtain marketing approval in China and enter the medical insurance directory in the future, providing treatment options for more patients.

Reference materials:https://empaveli.com/